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Background  :  The  expression  of  c-FLIP  (cellular  Fas-associated  death  domain-like  interleukin-1  β-converting 
enzyme  (FLICE)-inhibitory  protein),  which  is  a  member  of  the  family  of  inhibitors  of  apoptosis,  has  been  associated  with 
tumor  development  and  progression.  The  aim  of  this  study  was  to  evaluate  the  expression  of  c-FLIP  in  gastric  cancer 
and  its  correlation  with  tumor  cell  proliferation,  apoptosis  and  the  clinicopathologic  features. 
Methods  :  Immunohistochemical  staining  with  anti-c-FLIP  antibody  was  performed  in  98  tissue  samples  obtained 
from  gastric  cancer  patients  who  underwent  surgical  treatment.  The  apoptotic  cells  were  visualized  by  terminal 
deoxynucleotidyl  transferase  (TdT)  mediated  deoxyuridine  triphosphate  (dUTP)  nick-end  labeling  (TUNEL),  and  the 
proliferative  cells  were  visualized  by  staining  with  Ki-67  antibody. 
Results  :  The  positive  expression  of  c-FLIP  in  the  gastric  cancer  tissues  was  demonstrated  in  57.1%  of  the  cases. 
The  expression  of  c-FLIP  was  increased  in  the  gastric  cancer  tissues  compared  with  the  matched  normal  gastric 
mucosa.  The  expression  of  c-FLIP  was  significantly  associated  with  histologic  differentiation  (p=0.038).  However,  there 
was  no  association  between  the  c-FLIP  expression  and  the  other  clinicopathological  parameters,  including  patient 
survival.  The  Ki-67  labeling  index  (KI)  for  the  98  tumors  ranged  from  7.6  to  85.0  with  a  mean  KI  of  50.4±15.7.  The 
mean  KI  value  of  the  c-FLIP  positive  tumors  was  54.1±15.3  and  this  was  significantly  higher  than  that  of  the  c-FLIP 
negative  tumors  (p=0.005).  The  apoptotic  index  (AI)  for  the  98  tumors  ranged  from  0.0  to  10.0  with  a  mean  AI  of  7.4±
2.3.  There  was  no  significant  difference  between  the  c-FLIP  expression  and  the  AI  (p=0.347). 
Conclusions  :  These  results  suggest  that  the  c-FLIP  expression  may  be  associated  with  tumor  cell  proliferation  of 
gastric  cancer. 
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INTRODUCTION 
Apoptosis  plays  an  important  role  in  organ  homeostasis  by 
eliminating  senescent  or  damaged  cells.  Disturbance  of 
apoptosis  may  confer  a  survival  advantage  on  malignant  cells 
that  harbor  genetic  alterations  and  thus  promote  neoplastic 
progression
1-3).  Apoptosis  induction  may  occur  by  two  distinct 
signaling  pathways.  In  the  extrinsic  pathway,  apoptosis  is 
induced  through  the  binding  of  a  ligand  to  a  death  receptor  on 
the  cell  surface,  whereas  in  the  intrinsic  pathway,  apoptosis  is 
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event  in  apoptosis  is  the  proteolytic  activation  of  a  class  of 
cysteine  aspartyl-specific  proteases  termed  the  caspases. 
Initiator  caspases  cleave  effector  caspases,  which  in  turn 
degrade  a  number  of  intracellular  protein  substrates  and  thereby 
induce  the  characteristic  morphological  hallmarks  of  apoptosis. 
Specialized  initiator  caspases  are  located  at  the  top  of  both 
apoptosis  signaling  cascades.  Caspases-8  and  -10  are  mediators 
of  the  extrinsic  pathway,  and  caspase-9  initiates  the  intrinsic 
pathway
3, 4). 
Cellular  Fas-associated  death  domain-like  interleukin-1  β
-converting  enzyme  (FLICE)  inhibitory  protein  (c-FLIP)  is  a 
catalytically  inactive  caspase-8  and  caspase-10  homologue, 
and  its  gene  was  recently  identified  to  be  a  novel  antiapoptotic 
gene
5-8).  c-FLIP  is  recruited  to  death  receptor  signaling 
complexes,  where  it  inhibits  the  caspase  activation  that's 
responsible  for  apoptosis  and  this  activation  is  induced  by 
diverse  triggering  stimuli
5-8).  The  expression  of  c-FLIP  in  the 
vast  majority  of  human  cancers,  including  gastric  cancer,  is 
enhanced  and  associated  with  tumor  development  and 
progression
9-13). 
Regarding  tumor  cell  proliferation,  it  is  widely  accepted  that 
the  proliferative  capacity  may  influence  the  clinical  course  and 
hence,  the  patient  prognosis.  Ki-67  is  a  nuclear  antigen  that's 
expressed  in  all  stages  of  the  cell  cycle,  except  G0  and  early 
G1.  In  numerous  studies,  Ki-67  is  an  established  proliferation 
marker  and  it  has  been  extensively  used  to  estimate  the  growth 
fraction  of  tumors
14, 15). 
Tumor  development  and  progression  results  from  the 
imbalance  between  cell  proliferation  and  cell  death,  and  most  of 
this  occurs  through  apoptosis
16).  The  c-FLIP  expression  is 
believed  to  be  involved  in  tumor  development  and  progression 
by  affecting  cell  proliferation  and  apoptosis.  So,  the  aim  of  this 
study  was  to  evaluate  the  expression  of  c-FLIP  in  gastric 
cancer  and  to  determine  its  correlation  with  tumor  cell 
proliferation,  apoptosis  and  the  clinicopathologic  features. 
MATERIALS AND METHODS 
Patients  and  samples  selection 
We  studied  the  formalin-fixed  and  paraffin-embedded  tumor 
specimens  from  98  randomly  chosen  patients  who  had 
undergone  surgery  for  gastric  cancer  at  Chonnam  National 
University  Hospital  between  July  1993  and  June  1994.  None  of 
the  patients  had  received  preoperative  radiotherapy  or 
chemotherapy.  The  pathologic  reports  and  clinical  histories  at 
the  time  of  surgery  were  reviewed  from  the  medical  records. 
The  histologic  grade  was  classified  according  to  the  criteria  of 
Lauren  and  the  World  Health  Organization
17, 18).  The  tumor 
staging  was  in  accordance  with  the  American  Joint  Committee 
on  Cancer  (AJCC)  staging  system
19).  Survival  was  measured 
from  the  time  of  surgery  until  follow-up  at  September  2003.  This 
study  group  was  comprised  of  66  males  and  32  females.  The 
median  age  was  60.0±10.2  (mean±SD)  with  an  age  range 
from  33  to  79  years.  The  mean  size  of  tumor  was  5.1±2.5  cm 
(mean±SD)  with  a  range  from  0.5  to  13.0  cm.  The  mean 
follow-up  period  was  75.9  months  with  a  range  from  1.3  to 
119.8  months 
Immunohistochemistry 
All  procedures  for  the  immunohistochemical  staining  were 
done  by  the  Micro-Probe  staining  system,  which  is  based  on 
capillary  action
20).  Paraffin  sections  4  μm  in  thickness  with  a 
mounted  probe  on  the  slides  were  immunostained  with 
anti-rabbit  polyclonal  antibody  for  the  c-FLIP  antigen  (R&D 
systems,  Inc.,  NJ,  USA)  by  the  avidin-biotin  peroxidase  complex 
method.  The  sections  were  deparaffinized  and  heated  in  a 
microwave  oven  for  7  minutes  to  retrieve  the  antigens.  They 
were  immersed  in  0.6%  hydrogen  peroxide  for  10  minutes  to 
block  the  endogenous  peroxidase  activity.  The  primary  antibody, 
at  concentration  of  1:100,  was  diluted  in  phosphate-buffered 
saline  supplemented  with  5%  normal  horse  serum  and  1% 
bovine  serum  albumin,  and  then  this  was  incubated  with  the 
tissues  for  overnight  at  room  temperature.  Anti-mouse 
immunoglobulin  G  (Sigma,  St.  Louis,  MO)  labeled  with  biotin 
was  used  as  a  secondary  antibody  for  the  detection  of  the 
primary  antibodies,  and  the  slides  were  incubated  for  10 
minutes  at  45℃ with  this  secondary  antibody.  After  multiple 
rinses  with  universal  buffer,  the  streptavidin-alkaline  phosphatase 
detection  system  (Biomeda,  Foster,  CA)  was  applied  for  8 
minutes.  As  the  final  step,  the  slides  were  developed  for  10 
minutes  with  the  enzyme  substrate  3,  3-diaminobenzidine  (DAB, 
Sigma,  St.  Louis,  MO).  The  slides  were  counterstained  with 
hematoxylin  solution  for  3  minute  (Research  Genetics, 
Huntsville,  AL).  After  dehydration,  the  tissue  was  sealed  with  a 
universal  mount  (Research  Genetics,  Huntsville,  AL).  For 
negative  controls,  the  primary  antibody  was  omitted  and 
replaced  with  phosphate-buffered  saline. 
Assessment  of  the  FLIP  Expression 
To  quantiate  the  FLIP  expression,  a  scoring  method  was 
modified  from  that  by  Zhou  et  al
13).  The  staining  intensity  was 
classified  from  zero  (no  staining)  to  3  (strong  staining),  and  the 
percentage  of  the  staining  area  was  classified  as  0  for  no 
positive  staining  of  tumor  cells,  1  for  positive  staining  in  <10% 
of  the  tumor  cells,  2  for  positive  staining  in  10%  to  50%  of  the 
tumor  cells,  or  3  for  positive  staining  in  >50%  of  the  tumor  cells. 
A  staining  index  was  calculated  as  the  product  of  the  staining 
intensity  and  the  staining  area.  Assessment  of  the  staining  was 
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Figure  1.  Immunohistochemical  staining  of  c-FLIP  in  the  normal  gastric  mucosa  (A)  and  the  gastric  cancer  tissue  (B).  c-FLIP 
immunoreactivity  was  more  intense  in  the  cytoplasm  of  the  cancer  cells  than  that  of  the  normal  gastric  mucosa  (×200). 
Figure  2.  Immunohistochemical  staining  of  Ki-67  in  the  gastric 
cancer tissue. Ki-67 immunoreactivity was found in the nuclei of the 
cancer  cells  (×200).
Figure  3.  Detection  of  apoptotic  cells  and  bodies  (arrow)  by 
TUNEL  staining.  An  apoptotic  body  is  characterized  by  a  pyknotic 
nucleus  surrounded  by  a  shrunken  cytoplasm,  and  the  apoptotic 
body  is  separated  from  the  surrounding  cells  by  a  halo  (×400). 
knowledge  of  the  clinical  outcomes  such  as  the  tumor  stage, 
grade  and  survival.  Consensus  scores  were  assigned  for  each 
case  by  reviewing  the  slides  that  showed  discrepancies  in 
scoring.  All  sections  for  which  the  two  observers  disagreed  were 
re-evaluated  and  discussed.  There  was  total  agreement  on  the 
classification.  The  tumors  were  categorized  as  having  a  positive 
expression  (staining  index  ≥4)  or  a  negative  expression 
(staining  index  <4). 
Assessment  of  Tumor  Cell  Proliferation 
The  tumor  proliferative  cells  were  visualized  by  immunohist-
ochemically  staining  them  using  anti-Ki-67  antibody  (MIB-1; 
diluted  1:150;  Dakopatts,  Glostrup,  Denmark).  Distinct  nuclear 
immunoreactivity  for  Ki-67  was  considered  positive.  The  Ki-67 
labeling  index  (KI)  was  presented  as  the  number  of  Ki-67- 
positive  nuclei  per  1000  tumor  cell  nuclei.  The  determination  of 
KI  has  been  used  to  estimate  the  proliferative  ability  of  tumor 
cells. 
Detection  of  Apoptotic  cells  and  bodies 
Apoptotic  cells  were  detected  by  terminal  deoxynucleotidyl 
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Figure  4.  Kaplan-Meier  survival  curve  correlating  disease  specific 
survival  with  the  positive  (solid  line)  or  negative  (dotted  line) 
expression  of  c-FLIP. 
transferase  (TdT)-mediated  deoxyuridine  triphosphate  (dUTP) 
nick  end  labeling  (TUNEL)
21).  The  TUNEL  method  for  the 
detection  of  apoptotic  cells  in  the  4  μm  thick  sections  of  the 
formalin-fixed  and  paraffin-embedded  tissue  was  performed  by 
using  the  ApopTag
TM  Plus  In  Situ  Apoptosis  Detection  Kit 
(Intergen,  Purchase,  NY).  Briefly,  the  tissue  sections  were 
dewaxed  and  hydrated  in  a  graded  series  of  alcohol  solutions. 
After  they  had  been  digested  with  proteinase  K  (20  mg/mL; 
Sigma,  St.  Louis,  MO)  for  15  min  at  room  temperature,  the 
endogenous`  peroxidase  was  blocked  by  2%  hydrogen  peroxide 
(H2O2)  in  phosphate  buffered  saline.  TdT  incubation  was  then 
performed  for  120  min  at  37℃.  The  reaction  was  terminated  by 
prewarmed  working  strength  STOP/WASH  buffer  and  then  the 
sections  were  incubated  with  anti-digoxygenin  peroxidase  for  60 
min  at  room  temperature.  After  the  DAB  color  reaction,  nuclear 
counterstaining  was  performed  with  Mayer's  hematoxylin.  The 
positive  control  sections  were  treated  with  0.7  g/mL  DNase  I 
(Sigma,  St.  Louis,  MO)  in  potassium  cacodylate  buffer  (pH  7.2) 
for  10  min  before  treatment  with  TdT  buffer.  The  negative 
control  sections  were  treated  by  substituting  distilled  water  for 
working  strength  TdT  enzymes.  A  quantitative  method  for 
calculating  apoptotic  cells  was  used  by  two  independent 
pathologists.  All  the  sections  were  examined  in  high  power  fields 
(magnification  of  40×10).  The  fields  were  selected  in  the 
highest  labeled  area  per  case.  The  apoptotic  indices  (AI)  were 
expressed  as  a  number  of  positive  nuclei,  including  apoptotic 
bodies,  among  1000  tumor  cell  nuclei. 
Statistical  Analysis 
All  statistical  analyses  were  carried  out  using  the  Statistical 
Package  for  the  Social  Sciences  (SPSS/PC+  13.0,  Chicago,  IL). 
The  correlation  between  the  c-FLIP  expression  and  the 
clinicopathological  parameters  was  examined  by  χ
2-testing  and 
Fisher's  exact  test.  The  relationship  between  the  c-FLIP 
expression  and  the  KI  or  AI  was  evaluated  by  the  student  t  test. 
Survival  curves  were  calculated  according  to  the  Kaplan-Meier 
method  and  the  differences  were  tested  with  a  log-rank  test. 
The  Cox  regression  model  was  used  to  determine  the 
prognostic  significance  of  each  parameter  by  performing 
multivariate  analysis.  A  p-value  of  less  than  0.05  was  considered 
statistically  significant. 
RESULTS 
Expressions  of  c-FLIP  and  Ki-67  protein  and  the 
detection  of  apoptosis  in  tissue  specimens 
The  immunostaining  of  c-FLIP  was  predominantly  identified 
in  the  cytoplasmic  regions  of  cancer  cells  and  it  was  also 
detectable  in  the  normal  gastric  mucosa,  while  it  was  not 
detectable  in  the  stromal  compartment  (Figure  1A,  B).  The 
expression  of  c-FLIP  was  increased  in  the  gastric  cancer 
tissues  compared  with  the  matched  normal  gastric  mucosa. 
Based  on  our  criteria,  the  positive  expression  of  c-FLIP  in  the 
cancerous  tissues  was  57.1%  (56/98).  Ki-67  immunoreactivity 
was  almost  always  found  in  the  nuclei  of  cancer  cells  (Figure  2). 
Positive  cells  were  frequent  in  the  advancing  margin  of  the 
tumor.  The  standard  morphologic  criteria  for  identifing  apoptosis 
were  the  presence  of  beaded  or  shrunken  chromatin  and 
apoptotic  bodies  with  clear  halos
22).  Almost  all  the  positively 
stained  cells  and  bodies  were  considered  to  be  apoptotic  cells 
that  corresponded  morphologically  to  the  standard  criteria  of 
apoptotic  cells  (Figure  3).  Nonspecific  staining  in  necrotic  foci 
showed  faint,  diffuse  staining  and  this  could  be  distinguished 
from  the  apoptotic  nuclei  by  simple  morphological  examination. 
Correlations  between  the  expression  of  c-FLIP,  the  KI 
and  AI  and  the  clinicopathological  features 
The  correlations  between  the  c-FLIP  expression  and  the 
clinicopathological  parameters  are  shown  in  Table  1.  The 
expression  of  c-FLIP  was  significantly  associated  with  histologic 
differentiation  (p=0.038).  However,  there  was  no  association 
between  the  c-FLIP  expression  and  the  depth  of  invasion, 
tumor  stage,  the  status  of  the  lymph  nodes  anddistant 
metastasis.  Furthermore,  the  c-FLIP  expression  was  not 
associated  with  patient  survival  (p=0.231)  (Figure  4).  When  the 
KI,  AI  and  the  c-FLIP  status  and  the  clinicopathological 
parameters  were  analyzed  by  the  Cox  regression  model,  the  KI, 
AI  and  c-FLIP  status  were  not  found  to  be  independent 
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Clinicopathological  Parameters
Total
(n=98)
c-FLIP  Expression 
p
Negative  (n=42) Positive  (n=56)
Age  (years)
    <60
    ≥60
Sex
    Male
    Female
Tumor  size  (cm)
    <4.9
    ≥4.9
Lauren  Classification
    Intestinal
    Diffuse
    Mixed
Differentiation  grade*
    WD
    MD
    PD
TNM  stage
    I
    II
    III
    IV
Depth  of  tumor  invasion
    T1
    T2
    T3
    T4
Lymph  node  metastasis
    N0
    N1-3
Distant  metastasis
    M0
    M1
47
51
66
32
43
54
44
29
25
16
31
51
35
14
32
17
14
25
49
10
47
51
84
14
24
18
25
17
22
19
13
16
13
4
10
28
19
3
13
7
9
10
19
4
22
20
37
5
23
33
41
15
21
35
31
13
12
12
21
23
16
11
19
10
5
15
30
6
25
31
47
9
0.115
0.153
0.114
0.054
0.038
0.206
0.380
0.448
0.560
*WD,  well  differentiated;  MD,  moderately  differentiated;  PD,  poorly  differentiated  adenocarcinoma
Table  1.  Correlation  between  the  c-FLIP  expression  and  the  clinicopathological  parameters  of  gastric  cancer
c-FLIP  expression
Total
(n=98)
KI  No.
p
Mean±SD
  Negative
  Positive
42
56
45.4±14.8
54.1±15.3
0.005
KI,  Ki-67  labeling  index
Table 2. The relationship between the KI and the status of the c-FLIP 
expression  in  gastric  cancer
Differentiation  Grade
Total
(n=98)
KI  No.
p
Mean±SD
  WD
  MD
  PD
16
31
51
55.2±12.3
52.8±16.3
47.4±15.8
0.317
KI,  Ki-67  labeling  index;  *WD,  well  differentiated;  MD,  moderately 
differentiated;  PD,  poorly  differentiated  adenocarcinoma
Table 3. The relationship between the KI and the differentiation grade 
in  gastric  cancer
Correlation  between  the  expression  of  c-FLIP  and  the 
differential  grade  and  tumor  cell  proliferation 
The  KI  for  98  tumors  ranged  from  7.6  to  85.0  with  a  mean 
KI  of  50.4±15.7.  The  mean  KI  value  of  the  c-FLIP  positive 
tumors  was  54.1±15.3  and  this  was  significantly  higher  than 
that  of  the  c-FLIP  negative  tumors  (p=0.005)  (Table  2). 
However,  there  was  no  difference  between  the  differentiation 
grade  and  the  KI  (p=0.317)  (Table  3). 
Correlation  between  the  expression  of  c-FLIP  and  the 
differentiation  grade  and  apoptosis 
The  AI  for  the  98  tumors  ranged  from  0.0  to  10.0  with  a 
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c-FLIP  expression
Total
(n=98)
AI  No.
p
Mean±SD
  Negative
  Positive
42
56
7.2±2.2
7.6±2.4
0.347
AI,  Apoptotic  index 
Table 4. The relationship between the AI and the status of the c-FLIP 
expression  in  gastric  cancer 
Differentiation  Grade
Total
(n=98)
AI  No.
p
Mean±SD
  WD
  MD
  PD
16
31
51
8.6±1.3
7.2±2.5
7.2±2.3
0.074
AI,  Apoptotic  index;  *WD,  well  differentiated;  MD,  moderately 
differentiated;  PD,  poorly  differentiated  adenocarcinoma 
Table 5. The relationship between the AI and the differential grade 
in  gastric  cancer
between  the  c-FLIP  expression  and  the  differentiation  grade 
and  the  AI  (p=0.347)  (Table  4,  5). 
DISCUSSION 
Apoptosis  is  a  cellular  response  that  regulates  important 
processes  such  as  tissue  homoeostasis,  defense  against  certain 
pathogens  and  elimination  of  unwanted  cells.  Disturbance  of  this 
process  by  aberrantly  extending  the  viability  of  cells  or  favoring 
an  accumulation  of  transforming  mutations  is  thought  to 
contribute  to  carcinogenesis
1-3).  Apoptosis  is  a  highly  regulated 
process,  and  various  inhibitors  of  this  process  are  known  to 
interfere  with  many  steps  of  the  extrinsic  or  the  intrinsic 
pathway
3, 4). 
The  expression  of  c-FLIP,  which  is  a  member  the  family  of 
inhibitors  of  apoptosis,  has  recently  been  reported  in  various 
types  of  cancer,  including  gastric  cancer
9-13).  Our  study  showed 
that  the  expression  of  c-FLIP  is  increased  in  gastric  cancer 
tissue  compared  with  the  detectable  levels  in  the  matched 
normal  gastric  mucosa.  These  results  suggest  that  the 
c-FLIPexpression  is  implicated  in  gastric  carcinogenesis. 
The  c-FLIP  expression  has  been  reported  to  be  associated 
with  tumor  progression
9-13).  However,  in  our  study,  there  was  no 
association  between  the  c-FLIP  expression  and  the  depth  of 
invasion,  tumor  stage,  the  status  of  the  lymph  nodes,  distant 
metastasis  or  poor  survival.  Only  the  c-FLIP  expression  was 
significantly  associated  with  the  histologic  differentiation. 
Previous  studies  on  gastric  cancer  have  reported  contrary 
results.  Zhou  et  al  reported  that  the  c-FLIP  expression  is 
associated  with  lymph  node  metastasis
13),  and  Lee  et  al 
reported  that  there  is  no  correlation  between  the  histologic  types 
and  the  c-FLIP  expression
12).  These  discrepancies  may  have 
cone  about  because  of  the  different  methods  used  to  detect 
c-FLIP,  the  different  scoring  systems  and  the  different 
antibodies  used  in  immunohistochemistry  as  quantitative 
markers.  At  the  protein  level,  there  are  two  splicing  variants  for 
c-FLIP.  They  are  the  long  splice  form  of  c-FLIP  (c-FLIPL)  and 
the  short  splice  form  of  c-FLIP  (c-FLIPS).  c-FLIPS  contains  only 
two  N-terminal  death  effector  domains  (DEDs)  that  are  very 
similar  to  the  prodomains  of  caspase-8/-10.  In  contrast,  c-FLIPL 
is  identical  in  length  with  caspase-8,  which  also  contains 
N-terminal  tandem  DEDs,  but  its  caspase  domain  is  altered, 
rendering  it  enzymically  inactive.  Therefore,  c-FLIPL  has  the 
classical  structure  of  a  dominant-negative  inhibitor
23-25).  Zhou  et 
al  used  anti-c-FLIPL/S  antibody
13)  and  Lee  et  al  used 
anti-c-FLIPL  in  their  immunohistochemistry,  the  same  as  ours
12). 
To  date,  since  the  exact  roles  of  the  two  variants  of  c-FLIP  in 
the  extrinsic  apoptotic  pathway  are  not  fully  known,  so  further 
molecular  and  biochemical  understanding  of  c-FLIP  is 
necessary  before  any  changes  of  this  molecule  can  be  applied 
in  clinical  practice  as  a  prognostic  factor. 
Cell  proliferation  and  apoptosis  must  be  properly  balanced  in 
order  to  maintain  tissue  homeostasis
1-3).  However,  tumor 
development  and  progression  is  generally  regarded  as 
dependent  on  an  increased  proliferation  rate  and  an  apoptosis 
rate  that's  too  low  to  balance  cell  growth.  The  KI  has  been 
used  to  evaluate  cell  proliferation  activity
14,  15).  In  our  study,  the 
mean  KI  value  of  the  c-FLIP  positive  tumors  was  significantly 
higher  than  that  of  the  c-FLIP  negative  tumors.  Chen  et  al 
reported  that  c-FLIP  protein  in  endometrial  carcinoma  was 
significantly  associated  with  the  proliferating  cell  nuclear 
antigen-labeling  index,  which  is  known  as  another  proliferation 
marker
9).  These  results  suggest  that  the  c-FLIP  expression  may 
be  associated  with  tumor  cell  proliferation. 
c-FLIP  is  a  recently  identified  antiapoptotic  gene
5-8).  However, 
in  our  study,  no  significant  difference  was  seen  between  the 
c-FLIP  expression  and  the  AI.  There  are  several  possible 
explanations  for  this  contrary  result.  First,  the  steps  of  apoptosis 
are  not  dependent  on  c-FLIP  alone,  and  these  steps  are 
regulated  by  many  regulators,  including  survivin,  Fas  and 
nuclear  factor-kappa  B
3).  Second,  in  human  cancers,  the  overall 
expression  of  c-FLIP  as  reported  in  different  studies  is  difficult 
to  compare  due  to  the  different  score  systems  and  the  different 
antibodies  the  studies  used.  Third,  the  two  splicing  variants  of 
c-FLIP  may  acts  as  an  inhibitor  or  a  promotor  of  the  extrinsic 
apoptotic  pathway
7).Therefore,  the  exact  biochemical  understan-
ding  of  the  various  inhibitors  or  promotors  of  the  apoptotic 
pathway  may  provide  the  means  to  design  drugs  to  correct  the 
imbalance  between  apoptosis  and  proliferation,  and  this Dae-Yeul  Ryang,  et  al  :  Expression  of  c-FLIP  in  Gastric  Cancer 269
imbalance  that  is  found  in  human  cancers.  A  larger  study  would 
probably  resolve  this  issue. 
  In  summary,  the  expression  of  c-FLIP  was  increased  in  the 
gastric  cancer  tissues  compared  with  the  matched  normal 
gastric  mucosa.  The  expression  of  c-FLIP  was  significantly 
associated  with  histologic  differentiation.  However,  there  was  no 
association  between  the  c-FLIP  expression  and  the  depth  of 
invasion,  tumor  stage,  the  status  of  the  lymph  nodes,  distant 
metastasis  and  patient  survival.  The  mean  KI  value  of  the 
c-FLIP  positive  tumors  was  significantly  higher  than  that  of  the 
c-FLIP  negative  tumors.  There  was  no  significant  difference 
between  the  c-FLIP  expression  and  the  AI.  These  results 
suggest  that  the  c-FLIP  expression  may  be  associated  with  the 
tumor  cell  proliferation  of  gastric  cancer. 
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